High incidence of multisystemic reactions to zimeldine

Forty-five patients suffering from a major depression were administered zimeldine, amitriptyline or placebo (15 patients in each group) in a double-blind controlled study. In the zimeldine group, seven of the 14 patients treated for more than one week presented a toxic syndrome consisting in a sever...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1985, Vol.28 (1), p.67-71
Main Authors: LANGLOIS, R, COURNOYER, G, DE MONTIGNY, C, CAILLE, G
Format: Article
Language:English
Subjects:
Adult
Alanine Transaminase - blood
Alkaline Phosphatase - blood
Aspartate Aminotransferases - blood
Biological and medical sciences
Depressive Disorder - blood
Depressive Disorder - drug therapy
Drug toxicity and drugs side effects treatment
Female
Humans
Leukocyte Count
Male
Medical sciences
Middle Aged
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Platelet Count
Time Factors
Zimeldine - adverse effects
Zimeldine - analogs & derivatives
Zimeldine - blood
Zimeldine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty-five patients suffering from a major depression were administered zimeldine, amitriptyline or placebo (15 patients in each group) in a double-blind controlled study. In the zimeldine group, seven of the 14 patients treated for more than one week presented a toxic syndrome consisting in a severe prostration, fever, myalgias and arthralgias. In all patients presenting this syndrome, laboratory analyses revealed an elevation of alkaline phosphatase and of aspartate and alanine aminotransferases and a decrease in white blood cell and platelet counts. Three patients presented a mild proteinuria and hematuria. Although an immunological mechanism cannot be ruled out, several characteristics of this reaction suggest the formation of a metabolite of zimeldine with direct cellular toxicity. The relatively high starting dose of 200 mg/day of zimeldine administered in the present study and the increment to 300 mg/day after only seven days might have contributed to the high incidence of toxic reactions observed.
ISSN:0031-6970
1432-1041
DOI:10.1007/BF00635710